Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000
Debt
Debt-to-Equity Ratio-3.63
Current Ratio4.52
Quick Ratio4.52
Price-To-Earnings
Trailing P/E Ratio-2.05
Forward P/E Ratio-2.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.18 million
Price / Sales15.83
Cash FlowN/A
Price / CashN/A
Book Value($0.31) per share
Price / Book-4.16
Profitability
EPS (Most Recent Fiscal Year)($0.63)
Net Income$-183,760,000.00
Net Margins-475.36%
Return on EquityN/A
Return on Assets-62.18%
Miscellaneous
Employees347
Outstanding Shares382,590,000
Market Cap$547.11 million
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.12). The biopharmaceutical company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.02 million. The firm's revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) earnings per share. View Novavax's Earnings History.
When is Novavax's next earnings date?
What price target have analysts set for NVAX?
8 brokers have issued 12 month price objectives for Novavax's stock. Their forecasts range from $1.35 to $10.00. On average, they anticipate Novavax's stock price to reach $3.80 in the next year. This suggests a possible upside of 194.6% from the stock's current price. View Analyst Price Targets for Novavax.
What is the consensus analysts' recommendation for Novavax?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.
Are investors shorting Novavax?
Novavax saw a increase in short interest in July. As of July 31st, there was short interest totalling 56,569,517 shares, an increase of 2.4% from the July 13th total of 55,236,505 shares. Based on an average trading volume of 3,542,687 shares, the short-interest ratio is presently 16.0 days. Approximately 15.0% of the company's shares are short sold. View Novavax's Current Options Chain.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Solid Biosciences (SLDB), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Acorda Therapeutics (ACOR) and Cellectis (CLLS).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 70)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 58)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 52)
- Dr. Gregory M. Glenn, Pres of R&D (Age 64)
- Ms. Jill Hoyt, VP of HR & Admin.
Has Novavax been receiving favorable news coverage?
Headlines about NVAX stock have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Novavax earned a coverage optimism score of 0.06 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 44.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Novavax.
Who are Novavax's major shareholders?
Novavax's stock is owned by a number of of retail and institutional investors. Top institutional investors include RTW Investments LP (0.69%), Schwab Charles Investment Management Inc. (0.56%), Bank of New York Mellon Corp (0.45%), Millennium Management LLC (0.44%), Taylor Wealth Management Partners (0.33%) and Eagle Asset Management Inc. (0.33%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.
Which institutional investors are selling Novavax stock?
Which institutional investors are buying Novavax stock?
NVAX stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., DAFNA Capital Management LLC, GSA Capital Partners LLP, Taylor Wealth Management Partners, Schwab Charles Investment Management Inc., Bank of America Corp DE, B. Riley Financial Inc. and Bank of New York Mellon Corp. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $1.29.
How big of a company is Novavax?
Novavax has a market capitalization of $547.11 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NASDAQ NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
